Skip to content
stoqly
en · USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

CONMED vs LeMaitre Vascular

Add, change or remove companies; up to four.

KIRA’s take AI analyst

I put CONMED and LeMaitre Vascular side by side, using each one’s latest annual report. Here is what stands out:

Who comes out ahead

Of the 11 measures where higher (or lower) is clearly better, how many each company leads.

CONMED

CNMD

2/11

Piotroski F-scoreShare count change

LeMaitre Vascular

LMAT

9/11

Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityNet debt / EBITDA

Side by side

Best in the row

Latest fiscal year CNMD FY25 LMAT FY25
Size
Market cap $1.5B $2.1B
Revenue $1.4B $250M
Free cash flow $151M $74.5M
Net income $47.1M $57.7M
Growth
Revenue growth 5.2% 13.5%
5-year growth 9.8% 14.0%
Share count change 0.0% 0.7%
Profitability
Gross margin 54.6% 71.5%
Operating margin 7.5% 27.2%
Net margin 3.4% 23.1%
FCF margin 11.0% 29.8%
Return on capital 3.7% 25.5%
Return on equity 4.7% 15.8%
Balance sheet
Net debt $794M −$191M
Net debt / EBITDA 5.1x −2.4x
Dividends and buybacks $24.7M $19.9M
Valuation & quality
P/E — 29.6x
Piotroski F-score 6 5

Ten years

Revenue

CNMD LMAT

Operating margin

CNMD LMAT

Free cash flow

CNMD LMAT

Return on capital

CNMD LMAT

Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.

↑ ↓ to move · ↵ to open